Condition
Common Warts (Verruca Vulgaris)
Total Trials
5
Recruiting
3
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
80%
4 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 3 (3)
P 4 (1)
Trial Status
Recruiting3
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07457918Phase 3RecruitingPrimary
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
NCT07543926Not ApplicableNot Yet RecruitingPrimary
New Treatment of Common Wart
NCT07448844Phase 4Recruiting
Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
NCT07246590Phase 3Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
NCT05889845Phase 3CompletedPrimary
Candin for the Treatment of Common Warts
Showing all 5 trials